MatthewAnthonyMaurerMD

Oncology • New York, NY

Breast Cancer, Hematologic Oncology

Assistant Professor, Medicine, Columbia University College of Phys & Surg

Join to view full profile

Dr. Maurer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Maurer's full profile

Already have an account?

Office
1130 Saint Nicholas Ave
Room 217c
New York, NY 10032
Phone+1 212-851-4761

Fax+1 212-851-4572
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2004 - 2008
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2001 - 2004
Icahn School of Medicine at Mount SinaiClass of 2001

Certifications & Licensure

NY State Medical License 2002 - 2026

Clinical Trials

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors Start of enrollment: 2009 Sep 01
Completed
Phase 1
Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Study of Erlotinib and Metformin in Triple Negative Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 1
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

24 citations
Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review.
Jack Hartnett, Wael A. Jaber, Matthew Maurer, Brett W. Sperry, Mazen Hanna, Patrick Collier, Divyang Patel, Oussama M. Wazni, Eoin Donnellan> ;JACC. Cardiooncology. 2021 Oct 1
130 citations
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/ PTEN mutation
Yan Xing, Nan Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul A. Sahin, Argun Akcakanat, Yisheng Li, Vandana G. Abramson, Jennifer K. Litton, Mariana Chav...> ;Breast Cancer Research. 2019 Jul 5
11 citations
PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.
Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos> ;Oncotarget. 2018 May 18
16 citations
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Kevin Kalinsky, Joseph A. Sparano, Xiaobo Zhong, Eleni Andreopoulou, Bret Taback, Lisa S. Wiechmann, Sheldon Feldman, P Ananthakrishnan, A. Ahmad, Serge Cremers, Antho...> ;Clinical & Translational Oncology. 2018 May 7
12 citations
Diffuse cutaneous breast cancer metastases resembling subcutaneous nodules with no surface changes.
Jonathan E. Mayer, Matthew A. Maurer, Huyen T Nguyen> ;Cutis. 2018 Mar 1
9 citations
Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial
Kevin Kalinsky, Tian Zheng, Hanina Hibshoosh, X. Du, Prabhjot Mundi, J. Yang, S Refice, Sheldon Feldman, Bret Taback, Eileen P. Connolly, Katherine D. Crew, Matthew A....> ;Clinical & Translational Oncology. 2017 Feb 1
40 citations
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She, Sofia K. Gruvberger-Saal, Matthew Maurer, Yilun Chen, Mervi Jumppanen, Tao Su, Meaghan Dendy, Ying Ka Ingar Lau, Lorenzo Memeo, Hugo M. Horlings, Marc J....> ;BMC Cancer. 2016 Aug 2
27 citations
Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial
Heather Greenlee, Ann Ogden Gaffney, A. Corina Aycinena, Pamela Koch, Isobel R. Contento, Wahida Karmally, John M. Richardson, Zaixing Shi, Emerson A. Lim, Wei-Yann Ts...> ;Cancer Epidemiology, Biomarkers & Prevention. 2016 Nov 1
78 citations
Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+ breast cancers
Ruth Rodriguez-Barrueco, Jiyang Yu, Laura P. Saucedo-Cuevas, Mireia Olivan, David Llobet-Navas, Preeti Putcha, Veronica Castro, Eva Murga-Penas, Ana Collazo-Lorduy, Mi...> ;Genes & Development. 2015 Aug 1
27 citations
Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Laura Reimers, Parijatham S. Sivasubramanian, Dawn L. Hershman, Mary Beth Terry, Heather Greenlee, Julie Campbell, Kevin Kalinsky, Matthew Maurer, Ramona Jayasena, Ros...> ;The Breast Journal. 2015 Jul 1
¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors.
Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai W, Crew K, Maurer M, Kalinsky K, Hershman DL> ;J Acad Nutr Diet. 2015-05-01
29 citations
ResearchOriginal Research¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors
Heather Greenlee, Ann Ogden Gaffney, A. Corina Aycinena, Pamela Koch, Isobel R. Contento, Wahida Karmally, John M. Richardson, Emerson A. Lim, Wei-Yann Tsai, Katherine...> ;Journal of the Academy of Nutrition and Dietetics. 2015 May 1
PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.
Wang X, Li G, Koul S, Ohki R, Maurer M, Borczuk A, Halmos B> ;Oncotarget. 2015-04-09
39 citations
Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients
Kevin Kalinsky, Julie Ann Mayer, Xunhai Xu, Tam Pham, Karina Wong, Eligie Villarin, Tony J. Pircher, Mindy Brown, Matthew Maurer, Farideh Z. Bischoff> ;Clinical & Translational Oncology. 2015 Jan 23
16 citations
Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.
Katherine D. Crew, Tong Xiao, Thomas Ps, Mary Beth Terry, Mathew S. Maurer, Kevin Kalinsky, Sheldon Feldman, Lois Brafman, Refice, Dawn L. Hershman> ;International Journal of Food Science, Nutrition and Dietetics. 2015 Feb 23
45 citations
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast ca...
Sara M. Tolaney, Howard A. Burris, Elaina M. Gartner, Ingrid A. Mayer, Cristina Saura, Matthew Maurer, Eva Ciruelos, Agustin A. Garcia, Frank Campana, Bin Wu, Yi Xu, J...> ;Breast Cancer Research and Treatment. 2015 Jan 1
16 citations
Breast Cancer Prognostic Biomarker Using Attractor Metagenes and the FGD3–SUSD3 Metagene
Tai-Hsien Ou Yang, Wei-Yi Cheng, Tian Zheng, Matthew A. Maurer, Dimitris Anastassiou> ;Cancer Epidemiology, Biomarkers & Prevention. 2014 Dec 1
11 citations
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.
Kevin Kalinsky, Emerson A. Lim, Eleni Andreopoulou, Avni Mukund Desai, Zhezhen Jin, Yifan Tu, Hanina Hibshoosh, Antai Wang, Heather Greenlee, Katherine D. Crew, Matthe...> ;Cancer Investigation. 2014 Oct 9
41 citations
Metformin and erlotinib synergize to inhibit basal breast cancer
Ying-Ka Ingar Lau, Xing Du, Vinayak Rayannavar, Benjamin D. Hopkins, Jacquelyn Shaw, Eliana Bessler, Tiffany Thomas, Maira M. Pires, Megan Keniry, Ramon Parsons, Serge...> ;Oncotarget. 2014 Sep 2
58 citations
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kevin Kalinsky, Katherine D. Crew, Susan Refice, Tong Xiao, Antai Wang, Sheldon Feldman, Bret Taback, Aqeel Ahmad, Serge Cremers, Hanina Hibshoosh, Matthew Maurer, Daw...> ;Cancer Investigation. 2014 Apr 1
231 citations
A secreted PTEN phosphatase that enters cells to alter signaling and survival.
Benjamin D. Hopkins, Barry Fine, Nicole Steinbach, Meaghan Dendy, Zachary Rapp, Jacquelyn Shaw, Kyrie Pappas, Jennifer S. Yu, Cindy Hodakoski, Sarah M. Mense, Joshua U...> ;Science. 2013 Jul 26
32 citations
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer
Heather Greenlee, Katherine D. Crew, Theresa Shao, Grace Kranwinkel, Kevin Kalinsky, Matthew Maurer, Lois Brafman, Beverly J. Insel, Wei-Yann Tsai, Dawn L. Hershman> ;Supportive Care in Cancer. 2013 Apr 1
94 citations
Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors.
Dawn L. Hershman, Heather Greenlee, Danielle Awad, Kevin Kalinsky, Matthew Maurer, Grace Kranwinkel, Lois Brafman, Ramona Jayasena, Wei-Yann Tsai, Alfred I. Neugut, Ka...> ;Breast Cancer Research and Treatment. 2013 Mar 31
7 citations
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
Grace Clarke Hillyer, Alfred I. Neugut, Katherine D. Crew, Kevin Kalinsky, Matthew A. Maurer, Demetra Z. Rotsides, Jonathan P. Danaceau, Dawn L. Hershman> ;Journal of Oncology Practice. 2012 Jun 26
24 citations
Lack of Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures
Heather Greenlee, Jacquelyn Shaw, Ying-Ka Ingar Lau, Ali Naini, Matthew Maurer> ;Integrative Cancer Therapies. 2012 Apr 26
Join now to see all

Abstracts/Posters

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Matthew J. Maurer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Sickle Cell Cure Will Be Cost-Effective if Health Disparities Considered -Study FindsDecember 13th, 2022
Research Exposes Inequities in Health Care Access and Delivery for Blood DisordersDecember 10th, 2022
Father and Son Chiropractors Re-Brand to Offer Backbone for Better HealthNovember 29th, 2022
Join now to see all